@article{SchaeferFriedrichJorgensenetal.2018, author = {Sch{\"a}fer, Nadine and Friedrich, Maximilian and J{\o}rgensen, Morten Egevang and Kollert, Sina and Koepsell, Hermann and Wischmeyer, Erhard and Lesch, Klaus-Peter and Geiger, Dietmar and D{\"o}ring, Frank}, title = {Functional analysis of a triplet deletion in the gene encoding the sodium glucose transporter 3, a potential risk factor for ADHD}, series = {PLoS ONE}, volume = {13}, journal = {PLoS ONE}, number = {10}, doi = {10.1371/journal.pone.0205109}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176495}, pages = {e0205109}, year = {2018}, abstract = {Sodium-glucose transporters (SGLT) belong to the solute carrier 5 family, which is characterized by sodium dependent transport of sugars and other solutes. In contrast, the human SGLT3 (hSGLT3) isoform, encoded by SLC5A4, acts as a glucose sensor that does not transport sugar but induces membrane depolarization by Na\(^{+}\) currents upon ligand binding. Whole-exome sequencing (WES) of several extended pedigrees with high density of attention-deficit/hyperactivity disorder (ADHD) identified a triplet ATG deletion in SLC5A4 leading to a single amino acid loss (ΔM500) in the hSGLT3 protein imperfectly co-segregating with the clinical phenotype of ADHD. Since mutations in homologous domains of hSGLT1 and hSGLT2 were found to affect intestinal and renal function, respectively, we analyzed the functional properties of hSGLT3[wt] and [ΔM500] by voltage clamp and current clamp recordings from cRNA-injected Xenopus laevis oocytes. The cation conductance of hSGLT3[wt] was activated by application of glucose or the specific agonist 1-desoxynojirimycin (DNJ) as revealed by inward currents in the voltage clamp configuration and cell depolarization in the current clamp mode. Almost no currents and changes in membrane potential were observed when glucose or DNJ were applied to hSGLT3[ΔM500]-injected oocytes, demonstrating a loss of function by this amino acid deletion in hSGLT3. To monitor membrane targeting of wt and mutant hSGLT3, fusion constructs with YFP were generated, heterologously expressed in Xenopus laevis oocytes and analyzed for membrane fluorescence by confocal microscopy. In comparison to hSGLT3[wt] the fluorescent signal of mutant [ΔM500] was reduced by 43\% indicating that the mutant phenotype might mainly result from inaccurate membrane targeting. As revealed by homology modeling, residue M500 is located in TM11 suggesting that in addition to the core structure (TM1-TM10) of the transporter, the surrounding TMs are equally crucial for transport/sensor function. In conclusion, our findings indicate that the deletion [ΔM500] in hSGLT3 inhibits membrane targeting and thus largely disrupts glucose-induced sodium conductance, which may, in interaction with other ADHD risk-related gene variants, influence the risk for ADHD in deletion carriers.}, language = {en} } @phdthesis{Muehlemann2018, author = {M{\"u}hlemann, Markus}, title = {Intestinal stem cells and the Na\(^+\)-D-Glucose Transporter SGLT1: potential targets regarding future therapeutic strategies for diabetes}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-169266}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2018}, abstract = {The pancreas and the small intestine are pivotal organs acting in close synergism to regulate glucose metabolism. After absorption and processing of dietary glucose within the small intestine, insulin and glucagon are released from pancreatic islet cells to maintain blood glucose homeostasis. Malfunctions affecting either individual, organ-specific functions or the sophisticated interplay of both organs can result in massive complications and pathologic conditions. One of the most serious metabolic diseases of our society is diabetes mellitus (DM) that is hallmarked by a disturbance of blood glucose homeostasis. Type 1 (T1DM) and type 2 (T2DM) are the main forms of the disease and both are characterized by chronic hyperglycemia, a condition that evokes severe comorbidities in the long-term. In the past, several standard treatment options allowed a more or less adequate therapy for diabetic patients. Albeit there is much effort to develop new therapeutic interventions to treat diabetic patients in a more efficient way, no cure is available so far. In view of the urgent need for alternative treatment options, a more systemic look on whole organ systems, their biological relation and complex interplay is needed when developing new therapeutic strategies for DM. T1DM is hallmarked by an autoimmune-mediated destruction of the pancreatic β-cell mass resulting in a complete lack of insulin that is in most patients restored by applying a life-long recombinant insulin therapy. Therefore, novel regenerative medicine-based concepts focus on the derivation of bioartificial β-like cells from diverse stem cell sources in vitro that survive and sustain to secrete insulin after implantation in vivo. In this context, the first part of this thesis analyzed multipotent intestinal stem cells (ISCs) as alternative cell source to derive bioartificial, pancreatic β-like cells in vitro. From a translational perspective, intestinal stem cells pose a particularly attractive cell source since intestinal donor tissues could be obtained via minimal invasive endoscopy in an autologous way. Furthermore, intestinal and pancreatic cells both derive from the same developmental origin, the endodermal gut tube, favoring the differentiation process towards functional β-like cells. In this study, pancreas-specific differentiation of ISCs was induced by the ectopic expression of the pancreatic transcription factor 1 alpha (Ptf1a), a pioneer transcriptional regulator of pancreatic fate. Furthermore, pancreatic lineage-specific culture media were applied to support the differentiation process. In general, ISCs grow in vitro in a 3D Matrigel®-based environment. Therefore, a 2D culture platform for ISCs was established to allow delivery and ectopic expression of Ptf1a with high efficiency. Next, several molecular tools were applied and compared with each other to identify the most suitable technology for Ptf1a delivery and expression within ISCs as well as their survival under the new established 2D conditions. Success of differentiation was investigated by monitoring changes in cellular morphology and induction of pancreatic differentiation-specific gene expression profiles. In summary, the data of this project part suggest that Ptf1a harbors the potential to induce pancreatic differentiation of ISCs when applying an adequate differentiation media. However, gene expression analysis indicated rather an acinar lineage-determination than a pancreatic β-cell-like specification. Nevertheless, this study proved ISCs not only as interesting stem cell source for the generation of pancreatic cell types with a potential use in the treatment of T1DM but alsoPtf1a as pioneer factor for pancreatic differentiation of ISCs in general. Compared to T1DM, T2DM patients suffer from hyperglycemia due to insulin resistance. In T2DM management, the maintenance of blood glucose homeostasis has highest priority and can be achieved by drugs affecting the stabilization of blood glucose levels. Recent therapeutic concepts are aiming at the inhibition of the intestinal glucose transporter Na+-D-Glucose cotransporter 1 (SGLT1). Pharmacological inhibition of SGLT1 results in reduced postprandial blood glucose levels combined with a sustained and increased Glucagon-like peptide 1 (GLP-1) secretion. So far, systemic side effects of this medication have not been addressed in detail. Of note, besides intestinal localization, SGLT1 is also expressed in various other tissues including the pancreas. In context of having a closer look also on the interplay of organs when developing new therapeutic approaches for DM, the second part of this thesis addressed the effects on pancreatic islet integrity after loss of SGLT1. The analyses comprised the investigation of pancreatic islet size, cytomorphology and function by the use of a global SGLT1 knockout (SGLT1-/-) mouse model. As SGLT1-/- mice develop the glucose-galactose malabsorption syndrome when fed a standard laboratory chow, these animals derived a glucose-deficient, fat-enriched (GDFE) diet. Wildtype mice on either standard chow (WTSC) or GDFE (WTDC) allowed the discrimination between diet- and knockout-dependent effects. Notably, GDFE fed mice showed decreased expression and function of intestinal SGLT1, while pancreatic SGLT1 mRNA levels were unaffected. Further, the findings revealed increased isled sizes, reduced proliferation- and apoptosis rates as well as an increased α-cell and reduced β-cell proportion accompanied by a disturbed cytomorphology in islets when SGLT1 function is lost or impaired. In addition, pancreatic islets were dysfunctional in terms of insulin- and glucagon-secretion. Moreover, the release of intestinal GLP-1, an incretin hormone that stimulates insulin-secretion in the islet, was abnormal after glucose stimulatory conditions. In summary, these data show that intestinal SGLT1 expression and function is nutrient dependent. The data obtained from the islet studies revealed an additional and new role of SGLT1 for maintaining pancreatic islet integrity in the context of structural, cytomorphological and functional aspects. With special emphasis on SGLT1 inhibition in diabetic patients, the data of this project indicate an urgent need for analyzing systemic side effects in other relevant organs to prove pharmacological SGLT1 inhibition as beneficial and safe. Altogether, the findings of both project parts of this thesis demonstrate that focusing on the molecular and cellular relationship and interplay of the small intestine and the pancreas could be of high importance in context of developing new therapeutic strategies for future applications in DM patients.}, subject = {Stammzelle}, language = {en} } @article{RiegerBaehrMaureretal.2014, author = {Rieger, Johannes and B{\"a}hr, Oliver and Maurer, Gabriele D. and Hattingen, Elke and Franz, Kea and Brucker, Daniel and Walenta, Stefan and K{\"a}mmerer, Ulrike and Coy, Johannes F. and Weller, Michael and Steinbach, Joachim P.}, title = {ERGO: A pilot study of ketogenic diet in recurrent glioblastoma}, series = {International Journal of Oncology}, volume = {44}, journal = {International Journal of Oncology}, number = {6}, doi = {10.3892/ijo.2014.2382}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121170}, pages = {1843-52}, year = {2014}, abstract = {Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with recurrent glioblastoma. Patients were put on a low-carbohydrate, ketogenic diet containing plant oils. Feasibility was the primary endpoint, secondary endpoints included the percentage of patients reaching urinary ketosis, progression-free survival (PFS) and overall survival. The effects of a ketogenic diet alone or in combination with bevacizumab was also explored in an orthotopic U87MG glioblastoma model in nude mice. Three patients (15\%) discontinued the diet for poor tolerability. No serious adverse events attributed to the diet were observed. Urine ketosis was achieved at least once in 12 of 13 (92\%) evaluable patients. One patient achieved a minor response and two patients had stable disease after 6 weeks. Median PFS of all patients was 5 (range, 3-13) weeks, median survival from enrollment was 32 weeks. The trial allowed to continue the diet beyond progression. Six of 7 (86\%) patients treated with bevacizumab and diet experienced an objective response, and median PFS on bevacizumab was 20.1 (range, 12-124) weeks, for a PFS at 6 months of 43\%. In the mouse glioma model, ketogenic diet alone had no effect on median survival, but increased that of bevacizumab-treated mice from 52 to 58 days (p<0.05). In conclusion, a ketogenic diet is feasible and safe but probably has no significant clinical activity when used as single agent in recurrent glioma. Further clinical trials are necessary to clarify whether calorie restriction or the combination with other therapeutic modalities, such as radiotherapy or anti-angiogenic treatments, could enhance the efficacy of the ketogenic diet.}, language = {en} } @article{HoeggerKurlbaumMuelek2013, author = {H{\"o}gger, Petra and Kurlbaum, Max and M{\"u}lek, Melanie}, title = {Facilitated Uptake of a Bioactive Metabolite of Maritime Pine Bark Extract (Pycnogenol) into Human Erythrocytes}, series = {PLoS ONE}, journal = {PLoS ONE}, doi = {10.1371/journal.pone.0063197}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96656}, year = {2013}, abstract = {Many plant secondary metabolites exhibit some degree of biological activity in humans. It is a common observation that individual plant-derived compounds in vivo are present in the nanomolar concentration range at which they usually fail to display measurable activity in vitro. While it is debatable that compounds detected in plasma are not the key effectors of bioactivity, an alternative hypothesis may take into consideration that measurable concentrations also reside in compartments other than plasma. We analysed the binding of constituents and the metabolite δ-(3,4-dihydroxy-phenyl)-γ-valerolactone (M1), that had been previously detected in plasma samples of human consumers of pine bark extract Pycnogenol, to human erythrocytes. We found that caffeic acid, taxifolin, and ferulic acid passively bind to red blood cells, but only the bioactive metabolite M1 revealed pronounced accumulation. The partitioning of M1 into erythrocytes was significantly diminished at higher concentrations of M1 and in the presence of glucose, suggesting a facilitated transport of M1 via GLUT-1 transporter. This concept was further supported by structural similarities between the natural substrate α-D-glucose and the S-isomer of M1. After cellular uptake, M1 underwent further metabolism by conjugation with glutathione. We present strong indication for a transporter-mediated accumulation of a flavonoid metabolite in human erythrocytes and subsequent formation of a novel glutathione adduct. The physiologic role of the adduct remains to be elucidated.}, language = {en} } @phdthesis{Filatova2009, author = {Filatova, Alina}, title = {Mechanism and Control of Nuclear-Cytoplasmic Translocation of the Transporter Regulator RS1}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-38512}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2009}, abstract = {Das RS1 Protein (Gen RSC1A1) beteiligt sich an der Regulation des Na+-D-Glukose-kotransporters SGLT1 und einiger anderer Transporter. In subkonfluenten LLC-PK1 Zellen hemmt RS1 die Freisetzung von SGLT1 aus dem trans-Golgi-Netzwerk und die Transkription von SGLT1. W{\"a}hrend es sich in konfluenten Zellen haupts{\"a}chlich im Zytoplasma befindet, ist RS1 in subkonfluenten Zellen im Kern und im Zytoplasma lokalisiert. In der vorliegenden Arbeit wurden Mechanismus und Regulation der konfluenzabh{\"a}ngigen Kernlokalisation von RS1 untersucht. Dabel konnte gezeigt werden, dass die von Konfluenz abh{\"a}ngige Kernlokalisation von RS1 durch den Zellzyklus reguliert wird. In RS1 aus Sus scrofa (pRS1) wurde eine Sequenz identifiziert („nuclear shuttling signal", NS), die f{\"u}r die konfluenzabh{\"a}ngige Verteilung von RS1 verantwortlich ist und sowohl das Signal f{\"u}r die Kernlokalisation (NLS) als auch das Signal f{\"u}r den Export aus dem Kern (NES) beinhaltet. Die NLS und NES Signale von RS1 vermitteln die Translokation des Proteins in den Kern und aus dem Kern mit Hilfe von Importin \&\#946;1 bzw. CRM1, wobei die Verteilung von RS1 zwischen Kern und Zytoplasma durch die Aktivit{\"a}t des Exportsystems bestimmt wird. Es wurde gezeigt, dass die benachbarte Proteinkinase C (PKC) Phosphorylierungsstelle an Serin 370 von pRS1 die NS-gesteuerte Kernlokalisierung kontrolliert und f{\"u}r die vom Zellzyklus abh{\"a}ngige Kernlokalisation notwendig ist. Aufgrund der Ergebnisse der ortsgerichteten Mutagenese, PKC-Aktivierungsexperimenten und Massenspektrometrie-Analyse des Phosphorylierungsmusters von RS1 wurde ein Modell vorgeschlagen, das die Regulation der Kernlokalisation des RS1 Proteins in LLC-PK1 Zellen beschreibt. Dem Modell zufolge wird RS1 in subkonfluenten Zellen stark in den Kern bef{\"o}rdert, w{\"a}hrend der Export von RS1 aus dem Kern nicht stattfindet. Das f{\"u}hrt zur Anreicherung von RS1 im Kern. Nach Konfluenz wird Serin 370 durch PKC phosphoryliert, was die Steigerung des RS1-Exports aus dem Kern beg{\"u}nstigt und die {\"u}berwiegend zytoplasmatische Lokalisation des Proteins in konfluenten Zellen hervorruft. Die konfluenzabh{\"a}ngige Regulation der Lokalisation von RS1 kann die Expression von SGLT1 w{\"a}hrend der Regeneration von Enterozyten im D{\"u}nndarm und der Regeneration von Zellen der Nierentubuli nach hypox{\"a}mischem Stress kontrollieren. Außerdem deutet die Analyse der Genexpression in embryonalen Fibroblasten der RS-/- M{\"a}use deutet darauf hin, dass die transkriptionale Regulation durch RS1 im Zellzyklus und bei der Zellteilung eine wichtige Rolle spielen kann. Da die Lokalisation von RS1 zellzyklusabh{\"a}ngig ist, kann RS1 f{\"u}r die Regulation der Transporter in spezifischen Phasen des Zellzyklus wichtig sein.}, subject = {RS1}, language = {en} }